A carregar...
Compensatory angiogenesis and tumor refractoriness
Since the establishment of tumor angiogenesis as a therapeutic target, an excitement in developing the anti-angiogenic agents was resulted in tailoring a humanized monoclonal antibody (Bevacizumab) against vascular endothelial growth factor (VEGF): a key factor in recruiting angiogenesis. The past t...
Na minha lista:
| Publicado no: | Oncogenesis |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4753522/ https://ncbi.nlm.nih.gov/pubmed/26029827 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/oncsis.2015.14 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|